Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
The latest announcement is out from Pascal Biosciences Inc ( (TSE:NEVI) ).
Nevis Brands Inc. reported a slight increase in revenue for Q2 2025, driven by stable performance in its licensed markets and the introduction of its hemp-derived THC product line. Despite stable gross margins, the company faced a net loss due to foreign exchange pressures and elevated audit costs. Nevis continues to expand geographically, with growth in New Jersey and Missouri, and anticipates increased sales from its new hemp-derived THC beverage. The company’s asset-light licensing model supports high margins and adaptability to regulatory changes, positioning it for growth as the cannabis beverage market matures.
Spark’s Take on TSE:NEVI Stock
According to Spark, TipRanks’ AI Analyst, TSE:NEVI is a Neutral.
The overall score is influenced by moderate financial performance and valuation challenges. Positive corporate events provide a boost, highlighting strategic market expansion and revenue growth, but technical analysis indicates a lack of strong momentum.
To see Spark’s full report on TSE:NEVI stock, click here.
More about Pascal Biosciences Inc
Nevis Brands Inc. is a prominent player in the cannabis beverage industry, known for its innovative products consumed by millions across the United States. The company, led by its flagship brands Major™ and Happy Apple™, licenses and produces cannabis beverages through various production and distribution partners, rapidly expanding its product reach nationally. Nevis is publicly traded on the CSE, US OTC, and Frankfurt Stock Exchange.
Average Trading Volume: 32,394
Technical Sentiment Signal: Sell
Current Market Cap: C$2.18M
See more data about NEVI stock on TipRanks’ Stock Analysis page.